Alnylam Pharmaceuticals vs BeOne Medicines
ALNY and ONC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALNY and ONC compare
BeOne Medicines is the larger company, worth 25 times as much as Alnylam Pharmaceuticals ($547B against $22.1B).
BeOne Medicines scores higher on the StockData Score (12 against 7 for Alnylam Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALNY | ONC |
|---|---|---|
| Size and price | ||
| Market cap | $22.1B | $547B |
| Share price | $165.00 | $370.33 |
| Change, 1 year | −65.7% | 17.6% |
| Change, 5 years | −11.9% | 1.5% |
| Beta (5Y) | 0.88 | 1.07 |
| Employees | 2,500 | 12K |
| StockData Score | ||
| Total score | 7 | 12 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 1 | 4 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 861× |
| P/S | – | 89.3× |
| P/B | 6.1× (better) | 106× |
| EV/EBITDA | – | 504× |
| P/FCF | – | 412× |
| FCF yield | – | 0.24% |
| Fair value | – | $15.35 |
| Margin of safety | – | −2313% |
| Growth | ||
| Revenue growth (TTM) | – | 34.3% |
| Revenue growth, 5Y average | 49.8% | 76.8% (better) |
| Net income growth (TTM) | 2137% | – |
| Profitability | ||
| Gross margin | – | 88.9% |
| Operating margin | – | 15.1% |
| Net margin | – | 10.7% |
| FCF margin | – | 21.7% |
| Return on equity | 127% (better) | 14.7% |
| Return on invested capital | – | 43.7% |
| Financial health | ||
| Debt / equity | 0.00 | 0.22 (better) |
| Net debt / EBITDA | – | −3.67 |
| Interest coverage | – | 8.7× |
| Current ratio | 2.48 | 3.40 (better) |
| Altman Z-score | 2.75 | 82.54 (better) |
| Piotroski F-score | 6 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 99.8% | 2.4% |
| Held by insiders | 0.49% | 13.9% |
| Insider net buying, 12 months | −$43.6M (better) | −$369M |
| Short interest, % of float | 5.8% | – |
Go deeper
- ALNY stock overview
- ALNY income statement
- ALNY valuation and score
- ONC stock overview
- ONC income statement
- ONC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.